First, this issue marks the debut of our bonus section for AAFP members and paid FPM subscribers. The section, which is highlighted on the cover and again on the table of contents, follows page 16 and contains pages A1 through A8. (We will use the A prefix regularly to identify pages in the special section.) The section includes the CME Quiz, which offers 4.25 credits this month; an article on identifying drug-seeking patients by Richard W. Pretorius, MD, MPH, and Gina M. Zurick, PharmD, BCPS (page A3); and one on using group visits to help patients make behavioral changes by Jean Antonucci, MD (page A6). If the issue you are holding doesn't include the special section, it's because AAFP records show that you aren't an Academy member or an FPM subscriber. If you've been classified incorrectly, or if you'd like information on becoming a member or subscriber, please call the AAFP Member Resource Center at 800-274-2237.
Second, with this issue, access controls have been introduced on the FPM Web site as well as that of our sister publication, American Family Physician. While the bulk of FPM remains freely available, the most recent issues will be available only to AAFP members and FPM subscribers.
What does this look like in action? If you'll follow me to the FPM Web site (https://www.aafp.org/fpm), you'll notice that its design has changed to echo the new look of the AAFP Web site. You'll also see that FPM now carries advertising online as well as in print (as does American Family Physician). If you click on one of the article titles listed on the FPM home page, you'll find that you are asked to log in using your AAFP member number or your subscriber number. (To bypass this step in the future, click the “Remember me” box as you log in.) If you use the search box at the left of the FPM home page, you'll find search results labeled either “Members and Paid Subscribers Only” or “Free Full Text.” The latter can be viewed by anyone without logging in. Finally, as you browse the site, you'll see that ads do not appear on restricted-access articles. They will remain ad free.
There you have it. Several new bells and whistles, but the same useful journal underneath it all.